Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 2Lutetium-177 2Liquid Biopsy 2pentetreotide 1fluorodopa F 18 1copper dotatate CU-64 1Yttrium-90 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Single Photon Emission Computed Tomography Computed Tomography 1Resveratrol 1Respiratory Therapy 1Referral and Consultation 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Palliative Care 1Nutrition Assessment 1Needles 1Magnetic Resonance Spectroscopy 1Endoscopic Mucosal Resection 1Diet Therapy 1Data Collection 1Cryosurgery 1Control Groups 1Colectomy 1Betaine 190Y-octreotide, DOTA-Tyr(3)- 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Neuroendocrine Tumors × Lutetium-177 × Clear all
NCT04790708 2021-03-10

FENET-2016

University Hospital of Ferrara

Phase NA Unknown
250 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Instituto Nacional de Cancerologia, Columbia

Phase NA Completed
39 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡